It just got harder to sue over Glyphosate
A Missouri judge gave final approval to Bayer’s $7.25 billion settlement resolving Roundup cancer lawsuits, aiming to curb current and future claims without an admission of liability. The deal follows Bayer’s 2018 acquisition of Monsanto and inheritance of about 65,000 suits alleging glyphosate-based weedkiller exposure caused cancers like non-Hodgkin’s lymphoma. While individual payouts may be modest, the decision marks a strategic milestone to dampen ongoing litigation, even as past court defeats and questions about research integrity linger. The settlement echoes a broader shift toward limited liability for the company, with supporters calling it timely justice and critics warning it may soften accountability. The path forward suggests continued scrutiny of glyphosate science and further legal risk management by Bayer.
Dive Deeper:
The Missouri court granted final approval to Bayer's $7.25 billion settlement of Roundup class-action lawsuits, with the agreement designed to resolve current and future claims and close the courthouse doors to additional restitution seekers.
Bayer acquired Monsanto in 2018 and inherited roughly 65,000 lawsuits filed over the previous decade, most alleging that Roundup's glyphosate caused cancers such as non-Hodgkin’s lymphoma.
Individual awards are expected to be modest, estimated to range from about $10,000 to $100,000 per plaintiff, despite the large headline settlement total.
Proponents, including court-appointed lawyer Christopher A. Seeger, framed the approval as guaranteed compensation for victims who had waited more than a decade, while Bayer emphasized litigation containment rather than liability admission.
The litigation landscape has seen mixed outcomes: a $10 billion settlement in 2020, a Supreme Court ruling five months prior limiting liability in a related case, and ongoing scrutiny of studies linked to glyphosate’s safety, including ghostwriting allegations and later retractions.
Public discourse surrounding glyphosate includes claims of industry influence on research, with investigations noting Monsanto's role in shaping or concealing certain papers, fueling broader regulatory and scientific debates.
Looking ahead, the final approval is viewed as a strategic milestone by Bayer to mitigate risk from pending and future Roundup litigation, while observers expect continued legal, scientific, and policy challenges related to glyphosate.